--- title: "Rocket Pharmaceuticals (RCKT) news: class action and offering" url: "https://aibio.space/companies/rocket-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "RCKT class action and offering news: Rocket Pharmaceuticals faces securities class action and derivative suit over Danon trial. Rocket Pharmaceuticals, Inc." --- RCKT Rocket Pharmaceuticals, Inc. NASDAQ · United States # Rocket Pharmaceuticals (RCKT) news RCKT class action and offering news Debt Financing · 2026-10-06 ## [Rocket Pharmaceuticals secures credit facility of up to $150 million](https://aibio.space/news/rocket-pharmaceuticals-secures-credit-facility-up-150-million-hercules/) Hercules Capital is the lender. Rocket received $35 million at closing, reported no revenue in 2025 or 2024, and held $283.7 million in cash and investments at June 30, 2026. ## Latest Rocket Pharmaceuticals news 1. 2026-10-06 Debt Financing [Rocket Pharmaceuticals secures credit facility of up to $150 million from Hercules](https://aibio.space/news/rocket-pharmaceuticals-secures-credit-facility-up-150-million-hercules/) Rocket Pharmaceuticals received $35 million at closing under a credit facility of up to $150 million with Hercules Capital. The company expects its cash, with that first draw, to fund operations into the third quarter of 2028, and it says more borrowing could extend that into 2029. 2. 2026-08-10 Legal [Rocket Pharmaceuticals faces securities class action and derivative suit over Danon trial](https://aibio.space/news/rocket-pharmaceuticals-faces-securities-class-action-derivative-suit/) Ho and Yankov complaints named Rocket, CEO Gaurav Shah and former CFO Aaron Ondrey. Rocket's motion to dismiss the consolidated complaint is pending, and a derivative suit is stayed. 3. 2026-06-12 Mergers [Rocket Pharmaceuticals closes $180 million sale of priority review voucher](https://aibio.space/news/rocket-pharmaceuticals-closes-180-million-sale-priority-review-voucher/) Rocket received $180.0 million in gross proceeds from a large pharmaceutical company. It says pro forma cash of approximately $322.6 million should fund operations into the second quarter of 2028. 4. 2025-07-23 Distress [Rocket Pharmaceuticals starts restructuring with workforce reduction of about 30%](https://aibio.space/news/rocket-pharmaceuticals-starts-restructuring-workforce-reduction-about/) Rocket says the plan, approved by its board on June 18, 2025, aims to extend its operational runway into the second quarter of 2027. The company expects about $3.5 million in charges in the second half of 2025, against a 2024 operating cash outflow of $209.7 million. 5. 2024-12-10 Financings [Rocket Pharmaceuticals launches $150,000,000 stock offering, prices at $12.50](https://aibio.space/news/rocket-pharmaceuticals-launches-150-000-000-stock-offering-prices-12/) Rocket Pharmaceuticals priced 13,200,000 shares at $12.50 on December 10, 2024, below the $13.84 last sale price on December 9. Net proceeds are about $154.8 million before the underwriters' option, and the company's own prospectus says the money will last into the second quarter of 2026. ## Rocket Pharmaceuticals at a glance - **Ticker**: RCKT - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $283.7 million ### Related companies - [Arrowhead Pharmaceuticals](https://aibio.space/companies/arrowhead-pharmaceuticals/) NASDAQ: ARWR - [First Tracks Biotherapeutics](https://aibio.space/companies/first-tracks-biotherapeutics/) NASDAQ: TRAX - [Hemab Therapeutics Holdings](https://aibio.space/companies/hemab-therapeutics/) NASDAQ: COAG - [BANGI INC](https://aibio.space/companies/bangi/) OTC: BNGI - [NANOLOGIX INC](https://aibio.space/companies/nanologix/) OTC: NNLX - [Amarantus Bioscience Holdings](https://aibio.space/companies/amarantus-bioscience/) OTC: AMBS - [Scribe Therapeutics](https://aibio.space/companies/scribe-therapeutics/) NASDAQ: SCTX - [BioCardia](https://aibio.space/companies/biocardia/) NASDAQ: BCDA ### Also on NASDAQ - [Pharvaris](https://aibio.space/companies/pharvaris-n-v/) PHVS - [Fate Therapeutics](https://aibio.space/companies/fate-therapeutics/) FATE - [Cumberland Pharmaceuticals](https://aibio.space/companies/cumberland-pharmaceuticals/) CPIX - [Veru](https://aibio.space/companies/veru/) VERU - [Ardelyx](https://aibio.space/companies/ardelyx/) ARDX - [Maze Therapeutics](https://aibio.space/companies/maze-therapeutics/) MAZE ## Rocket Pharmaceuticals annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$0](https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/) | [$0](https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/) | | Research and development | [$142.0 million](https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/) | [$171.2 million](https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/) | | Net income (loss) | [-$223.1 million](https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/) | [-$258.7 million](https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/) | | Cash from operations | [-$190.0 million](https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/) | [-$209.7 million](https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/) | | Cash and equivalents | [$77.6 million](https://www.sec.gov/Archives/edgar/data/1281895/000119312526342348/) | [$163.6 million](https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/) | | Short-term investments | [$111.4 million](https://www.sec.gov/Archives/edgar/data/1281895/000119312526342348/) | [$208.7 million](https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $224.5 million, plus short-term investments of $59.2 million, $283.7 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Rocket Pharmaceuticals Is there a class action against Rocket Pharmaceuticals? Our latest story on this, dated Aug 10, 2026: "Rocket Pharmaceuticals faces securities class action and derivative suit over Danon trial". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/rocket-pharmaceuticals-faces-securities-class-action-derivative-suit/). Has Rocket Pharmaceuticals raised money recently? Our latest story on this, dated Dec 10, 2024: "Rocket Pharmaceuticals launches $150,000,000 stock offering, prices at $12.50". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/rocket-pharmaceuticals-launches-150-000-000-stock-offering-prices-12/). What is the ticker symbol of Rocket Pharmaceuticals? Rocket Pharmaceuticals, Inc. trades under the ticker RCKT on NASDAQ. Where is Rocket Pharmaceuticals listed? Rocket Pharmaceuticals, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:9IP1; LS:A2JA9Q; LSX:A2JA9Q. What is the SEC CIK of Rocket Pharmaceuticals? The SEC Central Index Key (CIK) for Rocket Pharmaceuticals, Inc. is 1281895. Its filings are on SEC EDGAR. How many shares does Rocket Pharmaceuticals have outstanding? 109,774,597 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-10. Which country or territory is Rocket Pharmaceuticals listed under? Our directory records Rocket Pharmaceuticals, Inc. under United States. What does Rocket Pharmaceuticals do? Our directory classifies Rocket Pharmaceuticals, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Rocket Pharmaceuticals? The ISIN recorded for Rocket Pharmaceuticals, Inc. is US77313F1066. Does aibio.space cover Rocket Pharmaceuticals? aibio.space lists Rocket Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Rocket Pharmaceuticals incorporated? SEC records list its state or country of incorporation as DE. What was Rocket Pharmaceuticals's revenue last year? $0 for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Rocket Pharmaceuticals profitable? Rocket Pharmaceuticals, Inc. reported a net loss of $223.1 million for the fiscal year ended Dec 31, 2025, and used $190.0 million of cash in operations, per its annual report to the SEC. How much does Rocket Pharmaceuticals spend on research and development? $142.0 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Rocket Pharmaceuticals have? $283.7 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. ## Investor discussion: Rocket Pharmaceuticals Members talk about Rocket Pharmaceuticals (RCKT). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Rocket Pharmaceuticals, newest first. Each line links the filing it comes from. 1. 2026-10-06 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1281895/000114036126038818/ef20083350_ex99-1.htm) 2. 2026-06-12 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1281895/000114036126024997/ef20076119_ex99-1.htm) 3. 2026-04-27 Financings Offered to buy back its own securities. SEC Form SC TO-I. [Source](https://www.sec.gov/Archives/edgar/data/1281895/000114036126016865/ny20069837x2_sctoi.htm) 4. 2026-03-10 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1281895/000114036126008849/ny20066752x3_424b5.htm) 5. 2025-08-07 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1281895/000095017025104996/rckt-20250630.htm) 6. 2025-07-23 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05). [Source](https://www.sec.gov/Archives/edgar/data/1281895/000114036125026946/ef20052517_8k.htm) 7. 2024-12-10 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1281895/000114036124048911/ny20039717x1_424b5.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:RCKT on TradingView](https://www.tradingview.com/symbols/NASDAQ-RCKT/). ## SEC filings and registration - **SEC name**: Rocket Pharmaceuticals, Inc. - **CIK**: 1281895 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: RCKT (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 350 FIFTH AVENUE, NEW YORK, NY, 10118 - **Phone**: 646-440-9100 - **Shares outstanding**: 109,774,597 as of 2026-07-31 (10-Q filed 2026-08-10) - **Former names**: INOTEK PHARMACEUTICALS CORP ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1281895/000114036126038818/ef20083350_8k.htm) filed 2026-10-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1281895/000114036126036563/ef20082010_8k.htm) filed 2026-09-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1281895/000114036126034689/ef20081170_8k.htm) filed 2026-08-27 - [8-K](https://www.sec.gov/Archives/edgar/data/1281895/000114036126032028/ef20079821_8k.htm) filed 2026-08-10 - [10-Q](https://www.sec.gov/Archives/edgar/data/1281895/000119312526342348/rckt-20260630.htm) filed 2026-08-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1281895/000114036126030568/ef20079241_8k.htm) filed 2026-08-03 - [8-K](https://www.sec.gov/Archives/edgar/data/1281895/000114036126026982/ef20077135_8k.htm) filed 2026-06-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1281895/000114036126024997/ef20076119_8k.htm) filed 2026-06-12 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001281895), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Rocket Pharmaceuticals, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker RCKT, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Rocket Pharmaceuticals, Inc. - **Ticker**: RCKT - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US77313F1066 - **Other listed symbols**: GETTEX:9IP1; LS:A2JA9Q; LSX:A2JA9Q - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-RCKT/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/rocket-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Rocket Pharmaceuticals (RCKT) news: class action and offering", 2026-10-31, https://aibio.space/companies/rocket-pharmaceuticals/